The effects of tamoxifen and toremifene on bone cells involve changes in plasma membrane ion conductance.
Selective estrogen receptor modulators (SERMs), tamoxifen (Tam) and toremifene (Tor), are widely used in the treatment of breast cancer. In addition, they have been demonstrated to prevent estrogen deficiency-induced bone loss in postmenopausal women. These effects are thought to be caused by the interaction of the SERMs with the estrogen receptor, although SERMs have also been shown to conduct non-receptor-mediated effects such as rapid changes in membrane functions. We compared the effects of Tam, Tor, and 17beta-estradiol (E2) on the viability of rat osteoclasts and osteoblasts. Both Tam and Tor were found to cause osteoclast apoptosis in in vitro cultures, which was reversed by E2. In addition, at higher concentration (10 microM), both SERMs had an estrogen receptor-independent effect, which involved interaction with the plasma membrane as demonstrated with UMR-108 osteosarcoma cells by Tam and Tor, but not E2. A leak of protons leading to changes in intracellular pH was shown both in medullary bone derived membrane vesicles and in intact cells. These effects were followed by a rapid loss of cell viability and subsequent cell lysis. Our results show that both Tam and Tor have an ionophoric effect on the plasma membranes of bone cells and that these SERMs differed in this ability: Tor induced rapid membrane depolarization only in the presence of high concentration of potassium. These non-receptor-mediated effects may be involved in therapeutic responses and explain some clinical side effects associated with the treatment of patients with these SERMs.
Lehenkari
Petri
P
Department of Surgery and Anatomy, University of Oulu, Oulu, Finland. ppl@sun3.oulu.fi
Parikka
Vilhelmiina
V
Rautiala
Timo J
TJ
Weckström
Matti
M
Dahllund
Johanna
J
Härkönen
Pirkko L
PL
Väänänen
H Kalervo
HK
D000818:Animals; D002462:Cell Membrane / Q000187:drug effects; D004958:Estradiol / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D007473:Ion Channels / Q000187:drug effects*; D017136:Ion Transport; D010006:Osteoblasts / Q000187:drug effects*; D010010:Osteoclasts / Q000187:drug effects*; D051381:Rats; D013629:Tamoxifen / Q000494:pharmacology*; D017312:Toremifene / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D007473:Ion Channels; D013629:Tamoxifen; D004958:Estradiol; D017312:Toremifene